Monte Rosa Therapeutics, Inc.
GLUECIK 0001826457 · Every Form 4 filed by insiders at this issuer. See financials →
Annual report (10-K)
Latest 10-K filed Mar 17, 2026. Sentiment + YoY language diff vs prior year. Read sections →
Signal:Material rewriteFull-doc fallback
Full filing:tone -0.0126Δ-0.000282% similar+721/-874 ¶
Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.
Recent 8-K announcements
Per-item disclosure feed. Item 2.02 is the earnings release.
Top insiders
Most active reporters at Monte Rosa Therapeutics, Inc.
| Name | Roles | Filings |
|---|---|---|
| Warmuth Markus | OfficerDirector | 10 |
| Dunn Edmund | Officer | 8 |
| Janku Filip | Officer | 7 |
| Nickson Philip | Officer | 7 |
| Townson Sharon | Officer | 6 |
Showing 1-5 of 26
Page 1 of 6Next
Top performers
Insiders ranked by realized 90-day signed return on their open-market trades at Monte Rosa Therapeutics, Inc.. Minimum 3 scored trades. Returns are signed - a sale followed by a rally counts against the insider.
| # | Insider | Trades | Win rate | Avg | Median | Best | Worst |
|---|---|---|---|---|---|---|---|
| 1 | Warmuth Markus | 5 | 60% | +11.3% | +26.5% | +26.5% | -17.6% |
| 2 | Dunn Edmund | 7 | 14% | -17.2% | -9.2% | +4.7% | -46.2% |
| 3 | Versant Vantage I Gp, L.P. | 7 | 43% | -0.9% | -0.5% | +39.3% | -51.8% |
| 4 | Versant Vantage I Gp-Gp, LLC | 7 | 43% | -0.9% | -0.5% | +39.3% | -51.8% |
| 5 | Versant Vantage I, L.P. | 7 | 43% | -0.9% | -0.5% | +39.3% | -51.8% |
| 6 | Versant Venture Capital VI, L.P. | 7 | 43% | -0.9% | -0.5% | +39.3% | -51.8% |
| 7 | Versant Ventures VI Gp, L.P. | 7 | 43% | -0.9% | -0.5% | +39.3% | -51.8% |
| 8 | Versant Ventures VI Gp-Gp, LLC | 7 | 43% | -0.9% | -0.5% | +39.3% | -51.8% |
All filings
86 Form 4 / 4-A filings, newest first
| Filed | Top transaction | Shares | Price | Value | ||
|---|---|---|---|---|---|---|